$VKTX
Viking Therapeutics, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016018987 Filed on May 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.390M $1.400M $320.0K
YoY Change 334.38% 566.67% 100.0%
% of Gross Profit
Research & Development $1.877M $3.220M $139.0K
YoY Change 1250.79% 2200.0% 177.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.877M $4.620M $461.0K
YoY Change 307.16% 1220.0% 119.82%
Operating Profit -$461.0K
YoY Change 119.82%
Interest Expense -$15.46K -$250.0K $35.25K
YoY Change -143.86% -24.24% 1268.52%
% of Operating Profit
Other Income/Expense, Net -$319.6K -$220.0K -$5.250M
YoY Change -93.91% -110.58% 27240.01%
Pretax Income -$3.590M -$5.090M -$5.710M
YoY Change -37.13% -466.19% 2382.61%
Income Tax
% Of Pretax Income
Net Earnings -$3.587M -$5.090M -$5.711M
YoY Change -37.2% -466.19% 2394.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$398.0K -$1.014M -$1.403M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.30M $14.10M $300.0K
YoY Change 3666.67% 1662.5% 200.0%
Cash & Equivalents $3.959M $768.6K $327.0K
Short-Term Investments $7.300M $13.30M
Other Short-Term Assets $900.0K $1.100M $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.20M $15.20M $360.4K
YoY Change 3285.15% 1864.84% 260.4%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $200.0K $775.00
YoY Change 77319.35% 25706.45% -99.61%
Total Long-Term Assets $600.0K $237.5K $2.409M
YoY Change -75.09% -89.54% 1104.46%
TOTAL ASSETS
Total Short-Term Assets $12.20M $15.20M $360.4K
Total Long-Term Assets $600.0K $237.5K $2.409M
Total Assets $12.80M $15.44M $2.769M
YoY Change 362.21% 407.34% 823.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M $592.4K $1.879M
YoY Change -36.15% -67.64% 369.85%
Accrued Expenses $700.0K $1.400M $25.50M
YoY Change -97.25% -93.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $300.0K
YoY Change -100.0%
Total Short-Term Liabilities $1.918M $1.977M $27.71M
YoY Change -93.08% -91.22% 6827.17%
LONG-TERM LIABILITIES
Long-Term Debt $3.100M $2.200M $1.400M
YoY Change 121.43% 69.23% 600.0%
Other Long-Term Liabilities $1.900M $2.600M $1.500M
YoY Change 26.67% 85.71% 1400.0%
Total Long-Term Liabilities $5.000M $4.737M $2.900M
YoY Change 72.43% 78.46% 866.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.918M $1.977M $27.71M
Total Long-Term Liabilities $5.000M $4.737M $2.900M
Total Liabilities $7.000M $6.714M $30.61M
YoY Change -77.13% -73.33% 3726.05%
SHAREHOLDERS EQUITY
Retained Earnings -$49.13M -$45.55M -$27.85M
YoY Change 76.4% 105.7%
Common Stock $54.90M $54.28M $13.83K
YoY Change 396908.94% 419811.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.770M $8.725M -$27.84M
YoY Change
Total Liabilities & Shareholders Equity $12.76M $15.44M $2.769M
YoY Change 360.65% 407.34% 823.11%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015 Q1
OPERATING ACTIVITIES
Net Income -$3.587M -$5.090M -$5.711M
YoY Change -37.2% -466.19% 2394.71%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.730M -$3.300M -$410.0K
YoY Change 565.85% 650.0% 310.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.970M $1.960M
YoY Change
Cash From Investing Activities $5.970M $1.960M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -60.00K -30.00K -20.00K
YoY Change 200.0% -107.5%
NET CHANGE
Cash From Operating Activities -2.730M -3.300M -410.0K
Cash From Investing Activities 5.970M 1.960M
Cash From Financing Activities -60.00K -30.00K -20.00K
Net Change In Cash 3.180M -1.370M -430.0K
YoY Change -839.53% 3325.0% 330.0%
FREE CASH FLOW
Cash From Operating Activities -$2.730M -$3.300M -$410.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1097599
CY2015Q4 us-gaap Assets Current
AssetsCurrent
15201648
CY2016Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
515381
CY2015Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
157455
CY2016Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
80000
CY2015Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
80000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1918125
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1976812
CY2016Q1 vktx Accrued Interest Non Current
AccruedInterestNonCurrent
202882
CY2015Q4 vktx Accrued Interest Non Current
AccruedInterestNonCurrent
183611
CY2016Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3139861
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2151540
CY2016Q1 vktx Debt Conversion Feature Liability Noncurrent
DebtConversionFeatureLiabilityNoncurrent
1698671
CY2015Q4 vktx Debt Conversion Feature Liability Noncurrent
DebtConversionFeatureLiabilityNoncurrent
2370903
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
27624
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
97
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
97
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54902270
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54277716
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49132433
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45545445
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-195
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7370
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
5769739
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8724998
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12756902
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15439103
CY2015Q4 vktx Convertible Notes Payable Discount Noncurrent
ConvertibleNotesPayableDiscountNoncurrent
348460
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9683741
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9683741
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9683741
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9683741
CY2016Q1 us-gaap Revenues
Revenues
0
CY2015Q1 us-gaap Revenues
Revenues
0
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1877178
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138969
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
624554
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
903
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-187704
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15564
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
449701
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
37306
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
327007
CY2016Q1 vktx Unpaid Deferred Initial Public Offering Costs
UnpaidDeferredInitialPublicOfferingCosts
409414
CY2015Q1 vktx Unpaid Deferred Initial Public Offering Costs
UnpaidDeferredInitialPublicOfferingCosts
2057903
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-752680
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
62707
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2725124
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-410941
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
149360
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
6122000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5972640
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
57303
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17909
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1390239
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
322071
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-57303
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-17909
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3190213
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-428850
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
755857
CY2015Q1 vktx Change In Fair Value Of Accrued License Fees
ChangeInFairValueOfAccruedLicenseFees
-4960511
CY2016Q1 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
96547
CY2016Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400657
CY2015Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
171955
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-15461
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-35253
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-319571
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5250375
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3586988
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5711415
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7175
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3579813
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5711415
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9015778
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4073609
CY2016Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
48475
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p></div>
CY2016Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></div>
CY2016Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-09-24
CY2016Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2016Q1 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2016Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
9683741
CY2015Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6000000
CY2016Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
667963
CY2015Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1926391
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5757036
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2389135
CY2016Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
7293058
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
416
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
611
CY2016Q1 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
2
CY2016Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
6
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13342869
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7370
CY2016Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10907128
CY2016Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1698671
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13884371
CY2015Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
2370903
CY2016Q1 vktx Convertible Notes Payoff Value
ConvertibleNotesPayoffValue
2702882
CY2016Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.025
CY2015Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05
CY2016Q1 vktx Debt Instrument Long Term Maturities Due Date
DebtInstrumentLongTermMaturitiesDueDate
2017
CY2015Q1 vktx Debt Instrument Long Term Maturities Due Date
DebtInstrumentLongTermMaturitiesDueDate
2016
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1000000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
0.01
CY2014Q1 vktx Number Of Tranches
NumberOfTranches
2
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
168000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
633810
CY2015Q2 vktx Shares Repurchase Price Per Share
SharesRepurchasePricePerShare
0.00001
CY2015Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
366190
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
61566
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
365394
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
480818
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
846212
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
138118
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.48
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.25
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.94
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.10
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M29D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y8M16D
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.56
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.818
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0154
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
CY2016Q1 vktx Description Of Warrant
DescriptionOfWarrant
The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The warrant also provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022.
CY2016Q1 vktx Warrant Expiration Date
WarrantExpirationDate
2022-04-28
CY2016Q1 vktx Initial Public Offering Expiration Date
InitialPublicOfferingExpirationDate
2020-04-28
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
63010
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
10737
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
120792
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
247611
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
190337
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
558740
CY2016Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
11251626

Files In Submission

Name View Source Status
0001564590-16-018987-index-headers.html Edgar Link pending
0001564590-16-018987-index.html Edgar Link pending
0001564590-16-018987.txt Edgar Link pending
0001564590-16-018987-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vktx-10q_20160331.htm Edgar Link pending
vktx-20160331.xml Edgar Link completed
vktx-20160331.xsd Edgar Link pending
vktx-20160331_cal.xml Edgar Link unprocessable
vktx-20160331_def.xml Edgar Link unprocessable
vktx-20160331_lab.xml Edgar Link unprocessable
vktx-20160331_pre.xml Edgar Link unprocessable
vktx-ex311_8.htm Edgar Link pending
vktx-ex312_6.htm Edgar Link pending
vktx-ex321_9.htm Edgar Link pending